Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
2024年4月24日 - 11:00PM
Merus Announces Abstracts Accepted for Presentation at the 2024
ASCO Annual Meeting
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a
clinical-stage oncology company developing innovative, full-length
multispecific antibodies (Biclonics® and Triclonics®), today
announced the acceptance of three abstracts for presentation at the
2024 American Society of Clinical Oncology (ASCO) Annual Meeting,
being held in Chicago, Illinois on May 31- June 4, 2024.
Rapid oral presentation:
Title: Petosemtamab
(MCLA-158) with pembrolizumab as first-line (1L) treatment of
recurrent/metastatic (r/m) head and neck squamous cell carcinoma
(HNSCC): Phase 2 study Abstract #:
6014Session Title: Head and Neck
CancerSession Date and Time: June 3, 2024,
8:00-9:30 a.m. CT
The presentation concerns petosemtamab evaluated in combination
with pembrolizumab in patients with untreated advanced PD-L1+
HNSCC.
Rapid oral presentation:
Title: Phase I study
of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in
solid tumors, as monotherapy or in combination with pembrolizumab
Abstract #: 2520Session Title:
Developmental Therapeutics—ImmunotherapySession Date and
Time: June 2, 2024, 11:30 a.m.-1:00 p.m. CT
The presentation concerns MCLA-145 evaluated as monotherapy or
in combination with pembrolizumab in patients with solid
tumors.
Poster presentation:
Title: Efficacy and
safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in
non-small-cell lung cancer (NSCLC) with c-MET exon 14 skipping
mutations (METex14)Abstract #: 8583Session
Title: Lung Cancer—Non-Small Cell
MetastaticSession Date and Time: June 3, 2024,
1:30-4:30 p.m. CT
The presentation concerns MCLA-129 evaluated as monotherapy in
patients with locally advanced/metastatic METex14 NSCLC.
The abstracts will be available on the ASCO website on May
23, 2024 at 5:00 p.m. ET. The full presentations will be available
on the Merus website at the start of each session.
About PetosemtamabPetosemtamab, or MCLA-158, is
a bispecific Biclonics® low-fucose human full-length IgG1 antibody
targeting the epidermal growth factor receptor (EGFR) and the
leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5).
Petosemtamab is designed to exhibit three independent mechanisms of
action including inhibition of EGFR-dependent signaling, LGR5
binding leading to EGFR internalization and degradation in cancer
cells, and enhanced antibody-dependent cell-mediated cytotoxicity
(ADCC) and antibody-dependent cellular phagocytosis (ADCP)
activity.
About MCLA-145MCLA-145 is a Biclonics® T-cell
agonist that binds with high affinity and specificity to human
PD-L1 and CD137 in preclinical models. The unique immunostimulatory
profile of MCLA-145 derives from the potential to potently activate
immune effector cells in the context of the tumor microenvironment
while blocking inhibitory signals among T-cells within the same
immune cell population.
About MCLA-129MCLA-129 is an antibody-dependent
cellular cytotoxicity-enhanced Biclonics® that is designed to
inhibit the EGFR and c-MET signaling pathways in solid tumors.
Preclinical data have shown that MCLA-129 can effectively treat
TKI-resistant NSCLC in xenograft models of cancer. MCLA-129 is
designed to have two complementary mechanisms of action: blocking
growth and survival pathways to stop tumor expansion and
recruitment and enhancement of immune effector cells to eliminate
the tumor.
About Merus N.V.Merus is a clinical-stage
oncology company developing innovative full-length human bispecific
and trispecific antibody therapeutics, referred to as
Multiclonics®. Multiclonics® are manufactured using industry
standard processes and have been observed in preclinical and
clinical studies to have several of the same features of
conventional human monoclonal antibodies, such as long half-life
and low immunogenicity. For additional information, please visit
Merus’ website, X, and LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including without limitation statements regarding the clinical
development of petosemtamab, MCLA-145 and MCLA-129, future clinical
trial results or interim data, clinical activity and safety profile
in the on-going trials and planned abstracts and presentation.
These forward-looking statements are based on management’s current
expectations. These forward-looking statements are based on
management’s current expectations. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements, including, but not
limited to, the following: our need for additional funding, which
may not be available and which may require us to restrict our
operations or require us to relinquish rights to our technologies
or Biclonics®, Triclonics® and multispecific antibody candidates;
potential delays in regulatory approval, which would impact our
ability to commercialize our product candidates and affect our
ability to generate revenue; the lengthy and expensive process of
clinical drug development, which has an uncertain outcome; the
unpredictable nature of our early stage development efforts for
marketable drugs; potential delays in enrollment of patients, which
could affect the receipt of necessary regulatory approvals; our
reliance on third parties to conduct our clinical trials and the
potential for those third parties to not perform satisfactorily;
impacts of the market volatility; we may not identify suitable
Biclonics® or bispecific antibody candidates under our
collaborations or our collaborators may fail to perform adequately
under our collaborations; our reliance on third parties to
manufacture our product candidates, which may delay, prevent or
impair our development and commercialization efforts; protection of
our proprietary technology; our patents may be found invalid,
unenforceable, circumvented by competitors and our patent
applications may be found not to comply with the rules and
regulations of patentability; we may fail to prevail in potential
lawsuits for infringement of third-party intellectual property; and
our registered or unregistered trademarks or trade names may be
challenged, infringed, circumvented or declared generic or
determined to be infringing on other marks.
These and other important factors discussed under the caption
“Risk Factors” in our Annual Report on Form 10-K for the year ended
December 31, 2023 filed with the Securities and Exchange
Commission, or SEC, on February 28, 2024, and our other reports
filed with the SEC, could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
management’s estimates as of the date of this press release. While
we may elect to update such forward-looking statements at some
point in the future, we disclaim any obligation to do so, even if
subsequent events cause our views to change, except as required
under applicable law. These forward-looking statements should not
be relied upon as representing our views as of any date subsequent
to the date of this press release.
Biclonics®, Triclonics® and Multiclonics® are registered
trademarks of Merus N.V.
Merus NV (TG:2GH)
過去 株価チャート
から 4 2024 まで 5 2024
Merus NV (TG:2GH)
過去 株価チャート
から 5 2023 まで 5 2024